Ofatumumab
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma
One-Sentence Summary
Ofatumumab is a fully human anti-CD20 monoclonal antibody historically approved (as Arzerra) for chronic lymphocytic leukemia (CLL), though it is currently not marketed in Taiwan (0 licenses) and its Taiwan approved-indication text is not on file. Among 10 TxGNN-predicted indications in this evidence pack, the strongest and most clinically credible new signal is Follicular Lymphoma, supported by 16 clinical trials (including one randomized Phase 2 trial) and 18 publications. Note: several other TxGNN predictions in this pack (ranked #1, #2, #5) are CLL/SLL or its molecular subtypes — these likely overlap with ofatumumab’s known historical indication rather than representing genuinely new repurposing opportunities; this is flagged as a probable data gap in the
original_indicationsfield.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Taiwan regulatory data (0 licenses on file). Evidence within this pack indicates ofatumumab was historically approved internationally as Arzerra for CLL, withdrawn from market in 2019 — this is contextual information, not TFDA-sourced |
| Predicted New Indication | Follicular Lymphoma |
| TxGNN Prediction Score | 99.70% (score 0.99701, rank 3785) |
| Evidence Level | L2 |
| Market Status (Taiwan) | ✗ Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
The structured original_moa field is a flagged data gap (DG002), but the mechanism can be reconstructed from the evidence pack’s own trial and literature records: ofatumumab is a fully human IgG1κ monoclonal antibody that binds a distinct small-loop epitope on CD20, depleting CD20-positive B cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) (PMID 18535937, 22830942, NCT01077622).
Follicular lymphoma (FL) and CLL are both CD20-positive, B-cell-lineage lymphoproliferative malignancies. Ofatumumab’s efficacy was originally established in CLL (accelerated FDA approval 2009, EMA conditional approval 2010), and the same CD20-targeting mechanism is directly applicable to FL, which is also a CD20+ mature B-cell neoplasm.
The class analogy is strong: rituximab, the prototypical anti-CD20 antibody, is already standard of care in FL. Multiple prospective trials in this pack (front-line monotherapy, chemoimmunotherapy combinations, and a randomized Phase 2 comparison) directly test ofatumumab in FL populations, moving this beyond a purely mechanistic extrapolation into an indication with dedicated, disease-specific clinical evidence — unlike several other predictions in this pack (e.g., malignant spiradenoma, Langerhans cell histiocytosis) which lack any biological rationale for CD20 involvement.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01286272 | Phase 2 (Randomized) | Completed | 135 | CALGB 50904: ofatumumab+bendamustine vs. ofatumumab+bendamustine+bortezomib in untreated high-risk FL — highest-grade direct RCT evidence |
| NCT00394836 | Phase 2 | Completed | 116 | Single-arm international multicenter trial of ofatumumab monotherapy in rituximab-refractory FL |
| NCT01190449 | Phase 2 | Completed | 51 | CALGB trial of single-agent ofatumumab in previously untreated stage II–IV FL |
| NCT01239394 | Phase 2 | Completed | 43 | Ofatumumab as initial systemic treatment for indolent B-cell lymphoma, including FL |
| NCT01077518 | Phase 3 | Terminated | 346 | Randomized ofatumumab+bendamustine vs. bendamustine monotherapy in rituximab-unresponsive indolent B-NHL |
| NCT01294579 | Phase 2 | Completed | 49 | Ofatumumab+bendamustine followed by ofatumumab maintenance in relapsed indolent B-NHL (incl. FL) |
| NCT00494780 | Phase 2 | Completed | 59 | Two-dose ofatumumab combined with CHOP in previously untreated FL |
| NCT02710643 | Phase 2 | Completed | 110 | MIRO trial: radiotherapy ± ofatumumab in stage I/II FL, MRD-driven approach |
| NCT00742144 | Phase 1 | Completed | 6 | Japanese safety/tolerability/PK study of ofatumumab in FL and CLL |
| NCT01397591 | Phase 2 | Terminated | 3 | Ofatumumab+bortezomib in relapsed CD20+ DLBCL, FL, or MCL |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31174236 | 2019 | RCT | Cancer | CALGB 50904: ofatumumab+bendamustine ± bortezomib in previously untreated high-risk FL |
| 30723894 | 2019 | Phase 2 Cohort | Br J Haematol | CALGB 50901: single-agent ofatumumab in untreated low/intermediate-risk FL |
| 22389254 | 2012 | Multicenter Cohort | Blood | Ofatumumab monotherapy in rituximab-refractory FL (n=116); ORR 13% |
| 38937025 | 2024 | Cohort | Lancet Haematology | FIL MIRO: local radiotherapy + MRD-driven ofatumumab in early-stage FL, final results |
| 22409295 | 2012 | Phase 2 Cohort | Br J Haematol | Ofatumumab + CHOP (O-CHOP) as frontline chemoimmunotherapy for FL |
| 24443277 | 2014 | PK Study | J Clin Pharmacol | Population pharmacokinetics of ofatumumab across CLL, FL, and RA populations |
| 18390837 | 2008 | Phase 1/2 Trial | Blood | First clinical use of ofatumumab in relapsed/refractory FL |
| 29934061 | 2018 | Evidence Review | Clin Lymphoma Myeloma Leuk | Evidence-based review of anti-CD20 regimens in relapsed/refractory CLL, DLBCL, FL |
| 28983798 | 2017 | Review | Advances in Therapy | 20-year review of rituximab (anti-CD20 class) in B-cell hematologic malignancies |
| 21083037 | 2010 | Review | Expert Rev Hematol | Emerging therapeutic strategies in follicular lymphoma |
Market Authorization Information (Taiwan)
Currently no marketing authorization records are on file for ofatumumab in Taiwan (taiwan_regulatory.total_licenses = 0, market_status = Not marketed). No approved-indication text is available for extraction.
Cytotoxicity
Ofatumumab is an antineoplastic biologic (anti-CD20 monoclonal antibody used for CD20+ B-cell malignancies), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy — targeted anti-CD20 monoclonal antibody (CDC/ADCC-mediated B-cell depletion, not a conventional cytotoxic agent) |
| Myelosuppression Risk | Low as monotherapy; Medium when combined with chemotherapy backbones such as bendamustine, CHOP, or fludarabine-cyclophosphamide (as used in most trials above) |
| Emetogenicity Classification | Low (monoclonal antibody class; infusion-related reactions are the more relevant acute toxicity than emesis) |
| Monitoring Items | CBC with differential, infusion-reaction monitoring, hepatitis B reactivation screening (standard precaution for anti-CD20 agents), immunoglobulin levels |
| Handling Protection | Standard biologic infusion precautions; not classified under cytotoxic hazardous-drug handling regulations. Please refer to the SmPC for institution-specific protocols |
Safety Considerations
No structured safety data is available in this evidence pack (key_warnings, contraindications, and ddi are all data gaps or empty).
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Ofatumumab’s efficacy in Follicular Lymphoma is supported by an L2 evidence base — one randomized Phase 2 trial and multiple single-arm Phase 1/2 studies with consistent mechanistic rationale (anti-CD20 activity established in CLL and validated by the rituximab class precedent in FL). However, the drug currently has zero marketing authorizations in Taiwan, and two blocking/high-severity data gaps (TFDA label warnings/contraindications, structured MOA) remain unresolved.
To proceed, the following is needed:
- TFDA product label (warnings, contraindications) — DG001, Blocking, required before any S1 safety assessment
- Structured MOA data from DrugBank — DG002, High priority
- Manual review of the
original_indicationsdata source: this pack shows an empty field despite trial/literature evidence (e.g., NCT00824265, NCT01313689) indicating a prior CLL indication history — likely a data extraction gap rather than a true absence of prior indication - Regulatory pathway assessment for a currently unmarketed (Not marketed) product in Taiwan
- Clarification of whether TxGNN predictions ranked #1, #2, and #5 (CLL/SLL and its IGHV subtypes) represent genuinely new indications or rediscovery of the historical indication, before including them in any repurposing decision
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.